Overview

Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.

Status:
Terminated
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This study was to determine long-term safety and tolerability, and continued efficacy in lowering triglycerides of LCQ908 in subjects with Familial Chylomicronemia Syndrome (FCS) (HLP type I).
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals